Atlas Trials

Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors

Clinical trial NCT02881190 · COMPLETED

Trial details

NCT number
NCT02881190
Sponsor
RemeGen Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors
Start date
2015-12-14
Primary completion
2019-06-27
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.